International Urology and Nephrology最新文献

{"title":"Haemodialysis distress thermometer scale: Turkish validity and reliability study.","authors":"Serkan Budak","doi":"10.1007/s11255-025-04574-3","DOIUrl":"https://doi.org/10.1007/s11255-025-04574-3","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to translate and adapt the \"Haemodialysis Distress Thermometer Scale\" (HDDT) into Turkish and assess its validity and reliability.</p><p><strong>Methods: </strong>This study collected data from 223 haemodialysis patients across three public hospitals in Kütahya province, Türkiye, over a seven-week period.</p><p><strong>Results: </strong>In this study, the content validity index of the scale was determined to be 0.96. Validity analysis results indicated that factor loadings ranged between 0.45 and 0.82, the total variance explained was 59.25%, and the fit indices were X²/df = 1.149 and RMSEA = 0.026. Reliability analysis showed that the total Cronbach's α coefficient was 0.80, with item-total correlation coefficients ranging from 0.37 to 0.73. The cut-off score for the HDDT barometer was identified as 6.5. The final structure of the HDDT scale comprised 40 items, four factors, and an 11-point barometer, consistent with the original scale.</p><p><strong>Conclusion: </strong>The Turkish version of the HDDT is a valid and reliable instrument for assessing distress in patients undergoing haemodialysis treatment. It may serve as a valuable tool for nurses in identifying and addressing patient distress during haemodialysis care.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic goals for mitigating chronic kidney disease progression in kidney transplant recipients: a 2024 update.","authors":"Moisés Carminatti, Helio Tedesco-Silva, Helady Sanders-Pinheiro","doi":"10.1007/s11255-025-04575-2","DOIUrl":"https://doi.org/10.1007/s11255-025-04575-2","url":null,"abstract":"<p><strong>Purpose: </strong>In addition to allogeneic factors, kidney transplant recipients (KTR) remain exposed to non-allogeneic conditions, such as hypertension, proteinuria, anemia, bone mineral disorder, metabolic acidosis and hyperuricemia. These conditions contribute to the progression of chronic kidney disease (CKD). This paper reviews the latest updates on therapeutic goals and strategies to address these non-allogeneic risk factors.</p><p><strong>Methods: </strong>We undertook a literature review regarding the current recommendations and therapeutic targets for the treatment of non-allogeneic risk factors for CKD progression in KTR, as of 2024.</p><p><strong>Results: </strong>As evidence is limited, some factors' treatment is based on native CKD. Well supported by studies on KTR, the blood pressure target should be below 130/80 mmHg, and proteinuria ideally be kept under 500 mg/day, whenever possible due to its multifactorial nature, preferably through the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Revised optimal haemoglobin levels, and newly updated recommendations regarding treatment at earlier stages of bone mineral disorders, as well as other metabolic features and non-pharmacological interventions, are further addressed. A multidisciplinary approach with an individualized focus on treatment priorities for each patient leads to better therapeutic adherence and potentially improved outcomes.</p><p><strong>Conclusion: </strong>We summarize the updated treatment goals for CKD in KTR, which are feasible to apply in daily practice and can contribute to better long-term patient and graft function survival.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Identification of druggable genetic targets for prostate cancer risk based on mendelian randomization and single‑cell RNA sequencing.","authors":"Liantai Song, Xinyang He, Yibing Duan, Yifan Chi, Reng Li, Cancan Li, Yutian Liu, Mengxin Yang, Jiameng Wei, Yujia Zhao, Qian Xu","doi":"10.1007/s11255-025-04573-4","DOIUrl":"https://doi.org/10.1007/s11255-025-04573-4","url":null,"abstract":"","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative effects of dexmedetomidine on renal function in allogeneic kidney transplant patients: a meta-analysis.","authors":"Yong Guo, Gongbin Lan, Shanbiao Hu","doi":"10.1007/s11255-025-04576-1","DOIUrl":"https://doi.org/10.1007/s11255-025-04576-1","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Allogeneic kidney transplantation represents a cornerstone therapeutic strategy for patients diagnosed with end-stage renal disease. The perioperative management of these patients plays a crucial role in ensuring both optimal graft viability and favorable postoperative outcomes. Dexmedetomidine, a highly selective α2-adrenergic agonist, has attracted considerable attention for its potential renoprotective properties, which are attributed to its anti-inflammatory effects, suppression of sympathetic nervous activity, and ability to stabilize hemodynamics. This meta-analysis was undertaken to systematically integrate the current body of evidence regarding the impact of dexmedetomidine on perioperative renal function in recipients of allogeneic kidney transplants.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A systematic and comprehensive search of the literature was conducted using multiple databases-PubMed, Embase, Web of Science, Cochrane Library, and the China National Knowledge Infrastructure (CNKI)-up to March 2025. IEligible studies included those involving adult recipients of allogeneic kidney transplants, wherein dexmedetomidine was administered during the perioperative period, and renal function outcomes such as serum creatinine (Cr), blood urea nitrogen (BUN), urine output, or delayed graft function (DGF) were reported. Two reviewers independently extracted data to ensure objectivity and accuracy; disagreements were resolved by discussion. The pooled data were analyzed using a random-effects model. Statistical heterogeneity was quantified using the I&lt;sup&gt;2&lt;/sup&gt; statistic, while potential publication bias was assessed through funnel plot symmetry. Sensitivity analyses were conducted to evaluate the robustness of the synthesized results.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Eleven studies comprising 1417 patients were included. Compared to controls, dexmedetomidine significantly reduced serum creatinine levels (SMD = - 0.75, 95% CI - 1.18 to - 0.32, p &lt; 0.001; I&lt;sup&gt;2&lt;/sup&gt; = 84.1%) and BUN levels (SMD = - 0.87, 95% CI - 1.30 to - 0.44, p = 0.001; I&lt;sup&gt;2&lt;/sup&gt; = 74.5%). Urine output was significantly increased (SMD = 0.98, 95% CI 0.23 to 1.74, p &lt; 0.001; I&lt;sup&gt;2&lt;/sup&gt; = 90.0%). The incidence of delayed graft function was lower in the dexmedetomidine group (OR = 0.71, 95% CI 0.52 to 0.97, p = 0.616; I&lt;sup&gt;2&lt;/sup&gt; = 0.0%). Length of hospital stay was also reduced (SMD = - 0.16, 95% CI - 0.29 to - 0.04, p = 0.364; I&lt;sup&gt;2&lt;/sup&gt; = 5.9%). Sensitivity analyses confirmed the robustness of the results. No significant publication bias was detected.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The results of this meta-analysis support the renoprotective potential of dexmedetomidine when administered during the perioperative phase of allogeneic kidney transplantation. Its use is associated with improvements in key renal function markers, such as reductions in serum creatinine and BUN levels, as well as a decreased incidence of delayed graft funct","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complications after augmentation enterocystoplasty in children.","authors":"Alicia Gómez Sánchez, Cristina Tordable Ojeda, Sara Monserrat Proaño Landázuri, Daniel Cabezalí Barbacho, Andrés Gómez Fraile","doi":"10.1007/s11255-025-04558-3","DOIUrl":"https://doi.org/10.1007/s11255-025-04558-3","url":null,"abstract":"<p><strong>Introduction: </strong>In the pediatric population, lower urinary tract dysfunction, usually, is due to neurogenic or anatomic defects. In this context, when conservative treatment fails, augmentation enterocystoplasty is a treatment option with good functional results. Nevertheless, multiple complications have been associated with this technique.</p><p><strong>Methods: </strong>We conducted a retrospective review of the patients who underwent bladder augmentation surgery at our hospital over the past 25 years. Statistical analyses were performed to identify potential factors associated with the occurrence of complications.</p><p><strong>Results: </strong>A total of 34 patients underwent augmentation enterocystoplasty during the study period. A total of 90 complications were recorded in 30 patients (88.2%). The average number of complications per patient was 2.6 ± 1.9. Reintervention was required in 28 patients (82.4%) due to complications, with a mean of 2.29 reoperations per patient. The most frequent complication was lithiasis (17/90), followed by stoma-related issues in the catheterizable duct (14/90), and urinary tract infections (10/90). Patients with exstrophy (p = 0.0028, IRR 3.4, 95% CI 1.71-6.78), bladder neck surgery (p = 0.014, IRR 2.04, 95% CI 1.29-3.21), and catheterizable duct (p = 0.002, IRR 2.56, 95% CI 1.61-4.06) had a significantly higher number of complications.</p><p><strong>Conclusions: </strong>In our study, over 85% of patients who underwent bladder augmentation surgery experienced at least one complication during follow-up. The risk was significantly higher in patients with bladder exstrophy and in those who had a bladder neck procedure.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-sarcopenic effect of leucine-enriched branched-chain amino acid supplementation among elderly chronic kidney disease patients: a double-blinded randomized controlled trial.","authors":"Neti Sunsandee, Paramat Thimachai, Bancha Satirapoj, Ouppatham Supasyndh","doi":"10.1007/s11255-025-04560-9","DOIUrl":"https://doi.org/10.1007/s11255-025-04560-9","url":null,"abstract":"<p><strong>Background: </strong>Leucine, a branched-chain amino acid (BCAA), is an effective nutritional strategy to enhance skeletal muscle mass in aging populations. This study aimed to evaluate the effects of oral leucine-enriched BCAA supplementation on muscle mass, muscle synthesis biomarkers, and physical performance in elderly patients with chronic kidney disease (CKD).</p><p><strong>Methods: </strong>A randomized controlled trial was conducted among CKD patients aged over 65 years. The participants were randomly assigned to receive either oral mixed BCAA supplementation (60% leucine, 4.5 g/day; 20% valine, 1.5 g/day; 20% isoleucine, 1.5 g/day) (N = 29) or a placebo (N = 26) for 12 weeks. Muscle mass, serum insulin-like growth factor 1 (IGF-1), and myostatin levels were measured at baseline and after 12 weeks. A 3-day food record was reviewed by a dietitian, and functional capacity was assessed using handgrip and 6-min walk tests.</p><p><strong>Results: </strong>Fifty-five patients (mean age 75.4 ± 5.2 years) were enrolled. Daily protein and calorie intake were comparable between groups. At study conclusion, lean muscle mass significantly increased in the leucine group compared to placebo (0.4 kg [95% CI 0.1-0.7] vs. - 0.2 kg [95% CI - 0.6-0.2], P = 0.010). A significant difference in the percentage change in muscle mass was also observed (1.0 ± 1.8% vs. - 0.5 ± 2.6%, P = 0.014). No significant differences were found in muscle strength, serum myostatin, IGF-1, or adverse events.</p><p><strong>Conclusions: </strong>Leucine-enriched BCAA supplementation for 12 weeks significantly increased muscle mass but did not impact biomarkers of muscle activity or functional capacity in elderly CKD patients.</p><p><strong>Clinical trial registration: </strong>TCTR20200314003.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between parathyroid volume and calcium and phosphorus metabolism in maintenance hemodialysis patients based on Doppler ultrasound technology.","authors":"Shengjie Guo, Liping Liu, Chao Zou, Pingping Liang, Yurou Wang, Chengcheng Sun, Xiaosu Gan, Xiaofang Tian, Liying Yuan","doi":"10.1007/s11255-025-04561-8","DOIUrl":"https://doi.org/10.1007/s11255-025-04561-8","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the correlation between parathyroid glands (PTGs) volume and calcium and phosphorus metabolism in maintenance hemodialysis (MHD) patients with Doppler ultrasound.</p><p><strong>Methods: </strong>MHD patients at the Hemodialysis Center of the Third Affiliated Hospital of Zunyi Medical University from January 1, 2024, to January 31, 2024, were selected as study subjects. To investigate the correlation between the number and size of PTGs detected by bedside ultrasound and indicators of calcium and phosphorus metabolism.</p><p><strong>Results: </strong>A total of 135 patients were included, of whom 90 had explored hyperplastic PTGs and 45 did not. Correlation analysis showed a negative correlation between ultrasound total PTGs volume and with age (r = -0.222, P = 0.035), large platelet ratio (r = -0.262, P = 0.013), and mean platelet volume (r = -0.232, P = 0.028), and a positive correlation with parathyroid hormone (iPTH) (r = 0.268, P = 0.011), corrected serum calcium (r = 0.233, P = 0.027), taking cinacalcet (r = 0.252, P = 0.0.017), sevelamer carbonate (r = 0.352, P = 0.002) and compound α-ketoacid tablets (r = 0.478, P < 0.001). Multifactorial linear regression analysis showed a positive correlation between ultrasound total PTGs volume and the correlation with age (t = -3.071, 95% CI: -0.030 ~ -0.007), albumin (t = -2.242, 95% CI: -0.115 ~ -0.008), iPTH (t = 2.748, 95% CI: 0.001 ~ 0.002), corrected serum calcium (t = 2.484, 95% CI: 0.184 ~ 1.563) showed significant linear relationships.</p><p><strong>Conclusions: </strong>A significant linear correlation was observed between PTGs volume, assessed via Doppler ultrasound, and the variables of age, albumin, iPTH, and corrected serum calcium in MHD patients. Therefore, it is essential for MHD patients to be closely monitored and have these serological indices controlled.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)-based on real-world data analysis.","authors":"Shaolong Zhang, Chuanjian Chen, Chunhao Mo, Ning Fan, Zhongyun Ning, Zhiping Wang, Hui Ding","doi":"10.1007/s11255-025-04567-2","DOIUrl":"https://doi.org/10.1007/s11255-025-04567-2","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the efficacy and safety of RC48-ADC combined with PD-1 inhibitors in bladder preservation therapy for muscle-invasive bladder cancer (MIBC), and to explore the differences in treatment outcomes between primary and recurrent cases, as well as patients at different clinical stages.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 32 patients with clinically non-metastatic MIBC who received ≥ 3 cycles of RC48-ADC combined with PD-1 inhibitor therapy. Clinical efficacy was assessed through integrated imaging and histopathological evaluations.</p><p><strong>Results: </strong>Among the 32 patients, the 1-year progression-free survival (PFS) rate was 84.4%, the objective response rate (ORR) was 68.8%, and the 1-year bladder preservation rate was 68.8%. The primary group was superior to the recurrent group in PFS (94.7% vs. 69.2%), ORR (78.9% vs. 53.8%), and 1-year bladder preservation rate (78.9% vs. 53.8%). Similarly, T2-stage patients exhibited better clinical responses than T3-stage patients in PFS (85.0% vs. 75.0%), ORR (80.0% vs. 54.5%), and 1-year bladder preservation rate (80.0% vs. 54.5%). Treatment-related adverse events (AEs) were predominantly grade I-II, with no severe immune-related complications reported.</p><p><strong>Conclusions: </strong>The combination of RC48-ADC and PD-1 inhibitors significantly improves bladder preservation rates in MIBC patients with a favorable safety profile, particularly in primary and T2-stage cases. This regimen provides a personalized therapeutic strategy for patients unsuitable for conventional treatments.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The comparison of efficacy and safety of reusable and disposable-flexible ureteroscopes: case-control matching results of multicentric RIRSearch study group.","authors":"Mehmet Fatih Şahin, Hulusi Sıtkı Dayısoylu, Cenk Murat Yazıcı, Duygu Sıddıkoğlu, Önder Çınar, Murat Akgül, Hakan Çakır, Cem Başataç, Oktay Özman, Muhammet Fatih Şimşekoğlu, Kerem Teke, Mustafa Bilal Tuna, Eyüp Burak Sancak, Barbaros Başeskioğlu, Bülent Önal, Haluk Akpınar","doi":"10.1007/s11255-025-04545-8","DOIUrl":"https://doi.org/10.1007/s11255-025-04545-8","url":null,"abstract":"<p><strong>Purpose: </strong>Today, disposable flexible ureteroscopes are increasingly used in retrograde intrarenal surgery (RIRS) as an alternative to reusable flexible ureteroscopes. The comparison of the safety and effectiveness of these two devices is still a matter of debate. This study evaluates the efficacy and safety of disposable-flexible ureteroscopes vs reusable flexible ureteroscopes in RIRS.</p><p><strong>Materials and methods: </strong>The study included 1165 RIRS cases, and the patients were divided into two groups. Group 1 consisted of cases with reusable RIRS, 838 in total, while Group 2 consisted of disposable RIRS cases, 327 in total. Due to significant differences, case-control matching was performed, and subsequently, there were 229 patients in both groups. The demographic and clinical data of patients, stone characteristics, surgical data, perioperative and postoperative complications, postoperative urinary tract infection rate, duration of hospitalization, and stone-free rates (SFR) were analyzed and compared.</p><p><strong>Results: </strong>No demographic differences were observed between the two groups after case-control matching. While operative time, SFR, and postoperative infection rates were similar between the groups (p > 0.05), fluoroscopy (p = 0.001) and hospitalization (p = 0.029) times were statistically significantly lower in the disposable ureteroscopy group. Perioperative and postoperative complications were also lower in this group (p = 0.018 and p = 0.001 respectively).</p><p><strong>Conclusion: </strong>Our research indicates that single-use ureteroscopes are a strong alternative to reusable ureteroscopes, demonstrating similar efficacy and reduced complication rates in the treatment of upper urinary tract stones.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the prognosis of patients with renal cell carcinoma based on systemic immune inflammatory index and prognostic nutritional index.","authors":"Xi Jiang, Tingting Zhou, Chenjing Liu, Na Xu, Xiaobin Chen, Dong Wang","doi":"10.1007/s11255-025-04553-8","DOIUrl":"https://doi.org/10.1007/s11255-025-04553-8","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the prognostic value of preoperative systemic immune inflammatory index (SII) and prognostic nutritional index (PNI) in patients with renal cell carcinoma (RCC) undergoing surgery, and to establish a nomogram for predicting overall survival (OS).</p><p><strong>Methods: </strong>We retrospectively analyzed clinical data from 240 RCC patients who underwent surgery. SII and PNI values were calculated, and optimal cutoff value were determined by receiver operating characteristic curves. Patients were classified into high and low SII/PNI groups. Survival outcomes were assessed using Kaplan-Meier analysis and log-rank tests. Univariate and multivariate Cox regression models were used to identify independent prognostic factors, which were incorporated into a nomogram. The model's accuracy and discrimination were evaluated by the consistency index (C-index) and calibration curves.</p><p><strong>Results: </strong>The 1-, 3- and 5-year survival rates were significantly higher in low SII group were (98.10%, 92.30%, and 87.20%) compared to the high SII group (90.00%, 72.90%, and 57.40%), and higher in the high PNI group (97.60%, 93.00%, and 87.60%) compared to the low PNI group (86.90%, 67.90%, and 40.80%; P < 0.001). Multivariate Cox regression model analysis showed that SII, PNI, hemoglobin, tumor necrosis, surgical method, pathological type, AJCC stage and Fuhrman grade were independent prognostic factors. The nomogram model demonstrated excellent predictive ability with a C index was 0.915.</p><p><strong>Conclusions: </strong>Preoperative SII and PNI are independent predictors of postoperative prognosis in RCC patients. The constructed nomogram based on multiple factors provides accurate individualized survival predictions.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}